Naqvi Atta Abbas, Hassali Mohamed Azmi, Rizvi Mehwish, Zehra Ale, Nisa Zeb-Un-, Islam Md Ashraful, Iqbal Muhammad Shahid, Farooqui Maryam, Imam Mohammad Tarique, Hossain Mohammad Akbar, Khan Irfanullah, Iqbal Muhammad Zahid, Ali Majid, Haseeb Abdul
Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Front Pharmacol. 2020 Jul 17;11:1039. doi: 10.3389/fphar.2020.01039. eCollection 2020.
The aim was to validate the Urdu version of General Medication Adherence Scale (GMAS) in patients with rheumatoid arthritis disease.
A 2-month (March-April 2019) cross-sectional study was conducted in randomly selected out-patients with rheumatoid arthritis. The sample size was calculated using item-subject ratio of 1:20. The scale was evaluated for factorial, concrete, concurrent, and known group validities. Concrete validity was established by correlating scores of EQ-5D quality of life scale and GMAS adherence score. Concurrent validity was established by correlating the GMAS adherence score with pill count. Analyses for sensitivity were also conducted. Cut-off value was determined through receiver operator curve (ROC), and test-retest method was used to analyze internal consistency and reliability. Data were analyzed through IBM SPSS, IBM AMOS, and MedCalc software. The Urdu version of EQ-5D quality of life questionnaire was used with permission from developers (#ID20884). The study was approved by an ethics committee (#NOV:15).
A total of 351 responses were analyzed. The response rate was 98%. Reliability was in acceptable range, , Cronbach = 0.797. Factorial validity was established by calculation of satisfactory fit indices. Correlation coefficients for concrete and concurrent validities were = 0.687, p < 0.01 and = 0.779, p < 0.01, respectively. Known group validity was established as significant association of adherence score with insurance and illness duration (p < 0.05) that were reported. Sensitivity of the scale was 94%. Most patients had high adherence (N = 159, 45.3%).
The Urdu version of GMAS demonstrated adequate internal consistency and was validated. These results indicate that it is an appropriate tool to measure medication adherence in Pakistani patients with rheumatoid arthritis.
旨在验证类风湿关节炎患者通用药物依从性量表（GMAS）的乌尔都语版本。
于2019年3月至4月进行了为期2个月的横断面研究，随机选取类风湿关节炎门诊患者。样本量根据项目与受试者1:20的比例计算得出。对该量表进行了因子效度、内容效度、同时效度和已知群体效度评估。通过将EQ-5D生活质量量表得分与GMAS依从性得分相关联来确定内容效度。通过将GMAS依从性得分与药丸计数相关联来确定同时效度。还进行了敏感性分析。通过受试者操作特征曲线（ROC）确定临界值，并采用重测法分析内部一致性和可靠性。数据通过IBM SPSS、IBM AMOS和MedCalc软件进行分析。经开发者许可使用了EQ-5D生活质量问卷的乌尔都语版本（#ID20884）。该研究获得伦理委员会批准（#NOV:15）。
共分析了351份回复。回复率为98%。可靠性在可接受范围内，Cronbach's α = 0.797。通过计算令人满意的拟合指数确定了因子效度。内容效度和同时效度的相关系数分别为r = 0.687, p < 0.01和r = 0.779, p < 0.01。确定已知群体效度为依从性得分与所报告的保险和病程之间存在显著关联（p < 0.05）。该量表的敏感性为94%。大多数患者具有高依从性（N = 159, 45.3%）。
GMAS的乌尔都语版本显示出足够的内部一致性并得到了验证。这些结果表明，它是测量巴基斯坦类风湿关节炎患者药物依从性的合适工具。
